Azitra, Inc. (AZTR) - Q1 2026 10-Q Summary
Business Context and Reporting Period
Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing novel therapeutics for precision dermatology using genetically engineered microbes. The company operates as a single segment and is currently in the pre-commercialization phase with no product revenue. This report covers the quarterly period ended March 31, 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,927,240) | $(3,068,345) |
| Net Loss Per Share (Basic & Diluted) | $(0.25) | $(1.55) |
| Cash and Cash Equivalents (End of Period) | $10,051,003 | $3,206,710 |
| Working Capital | $9,210,360 | Filing text does not provide a clear value |
| Total Assets | $12,126,804 | Filing text does not provide a clear value |
| Total Liabilities | $1,646,521 | Filing text does not provide a clear value |
| Stockholders' Equity | $10,480,283 | Filing text does not provide a clear value |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by 27% to $3.93 million from $3.10 million.
- General & Administrative (G&A): Increased 28% to $2.37 million, primarily driven by a $624,000 impairment charge on deferred patent costs, increased legal fees, and consulting costs.
- Research & Development (R&D): Increased 25% to $1.56 million, driven by progress in the ATR-01 and ATR-04 clinical programs, offset by reduced costs in the ATR-12 program.
- Liquidity: Cash and cash equivalents increased significantly by approximately $7.98 million, rising from $2.07 million at the end of 2025 to $10.05 million. This was fueled by financing activities.
- Capital Structure: The company completed a Series A Preferred Stock offering in March 2026, raising approximately $10.4 million in net proceeds. Additionally, the company drew $215,950 from its Equity Line of Credit (ELOC).
Outlook, Risks, and Management Commentary
- Going Concern: Management has identified substantial doubt about the company's ability to continue as a going concern for the next twelve months due to an accumulated deficit of $72.4 million and a lack of revenue. The company expects to require significant additional funding to complete product development.
- Listing Compliance: The company received a deficiency letter from NYSE American in October 2025 regarding stockholders' equity requirements. A compliance plan was accepted in December 2025, with a deadline to regain compliance by April 1, 2027. Failure to comply could result in delisting.
- Internal Controls: Management identified a material weakness in internal controls related to a lack of adequate segregation of accounting functions. Disclosure controls and procedures were deemed ineffective as of March 31, 2026.
- Product Pipeline:
- ATR-12: Phase 1b trial for Netherton syndrome; initial safety results reported in H1 2025.
- ATR-04: Phase 1/2 trial for EGFRi-associated rash; first patient dosed in Q3 2025; initial data expected Q3 2026.
- ATR-01: IND-enabling studies ongoing for ichthyosis vulgaris.
- Risks: Risks include the inability to secure additional financing, potential delisting, trade policy changes affecting foreign manufacturers, and the inherent risks of clinical trial failures.
Investor Verification Checklist
- Verify the status of the NYSE American compliance plan and the timeline for regaining full listing standards by April 2027.
- Confirm the terms and remaining capacity of the $20 million Equity Line of Credit (ELOC) with Alumni Capital.
- Review the specific details of the Series A Preferred Stock conversion rights and the potential dilution impact (conversion into ~85 million shares).
- Monitor the progress of the remediation plan for the material weakness in internal accounting controls.
- Assess the burn rate relative to the $10.1 million cash balance to determine the runway for operations without further financing.